@prefix : <http://semanticscholar.org/cv-research/> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix fhir_link: <http://hl7.org/fhir/link/> .
@prefix ncit: <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sso: <http://semanticscholar.org/cv-research/> .
@prefix whocv: <http://semanticscholar.org/cv-research/WHO#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318921> dc:abstract "INTRODUCTION: This study assessed the feasibility, performance, and safety of Mirasol®-treated platelet concentrates (M-PC) stored for up to 7 days. METHODS: This prospective observational study was approved by the ethical committee of the University Clinic of Santiago de Compostela. Informed consent was asked from patients receiving M-PC. M-PCs were treated with the Mirasol system according to the manufacturer's instructions. Thrombocytopenic patients were transfused according to the Spanish transfusion guidelines. Post-transfusion platelet counts were measured at 1 h and/or 24 h after transfusion. Post-transfusion surveillance of patients was maintained during the study. RESULTS: Data from 54 evaluable patients and 135 transfusions were analyzed. The mean age of patients was 58 years. The mean age of M-PC at transfusion was 3.6 days. The mean platelet dose was 3.7 × 10(11). The transfusion responses measured as mean corrected count increment 1 h after transfusion (CCI(1h)) and CCI(24h) were 9,659 and 4,751, respectively. 65% of transfusions resulted in CCI(1h) values ≥ 7,500. 51% of transfusions resulted in CCI(24h) values ≥ 4,500. CONCLUSION: The use of M-PC in the supportive treatment proved to be safe and effective for this cohort of thrombocytopenic patients." ;
    dc:creator "['Vilariño, M. Dolores', 'Castrillo, Azucena', 'Campos, Alfredo', 'Kilian, Rachel', 'Villamayor, Mercedes', 'Cardoso, Marcia']" ;
    dc:identifier <http://dx.doi.org/10.1159/000447643>,
        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318921> ;
    dc:title "Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela" ;
    sso:source_x "PMC" .